Late Breaking Trials To Be Presented At TCT 2009 In San Francisco

Main Category: Cardiovascular / Cardiology
Also Included In: Conferences;  Clinical Trials / Drug Trials;  IT / Internet / E-mail
Article Date: 13 Aug 2009 - 2:00 PDT

email to a friend   printer friendly   opinions  

TCT will also host a forum on electronic medical records

WHAT:

The Cardiovascular Research Foundation has announced the late breaking trials that will be presented at TCT (Transcatheter Cardiovascular Therapeutics) 2009, the largest global medical and scientific symposium dedicated to interventional cardiovascular medicine.

TCT 2009 will also feature a new session on Electronic Medical Records (EMR). Leading experts will discuss the latest developments in EMR and its relevance to health care reform.

WHEN:

The TCT Scientific Symposium will be held September 21-25, 2009.

Late-breaking clinical trials will be highlighted during press conferences scheduled for Wednesday, September 23, Thursday, September 24, and Friday, September 25.

WEDNESDAY, SEPTEMBER 23

SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

COMPARE: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

ISAR-DESIRE 2: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Sirolimus-Eluting Stent Restenosis

SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Paclitaxel-Eluting and Sirolimus-Eluting Stents

LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer

FAME: Two-Year Follow-up from a Prospective Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease

THURSDAY, SEPTEMBER 24

CURRENT-PCI OASIS 7: A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS

COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

CHARISMA GENOMICS SUBSTUDY: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention

TRITON-TIMI 38 ECONOMIC SUBSTUDY: Cost-Effectiveness of Prasugrel vs. Clopidogrel from a Prospective Randomized Trial of Patients with ACS Undergoing PCI

PLATO INVASIVE: A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy

PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

FRIDAY, SEPTEMBER 25

SYMPLICITY I: One-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension

DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI

HORIZONS AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI

BCIS-1: A Prospective Randomized Trial of Intra-Aortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI

NORDIC-BALTIC BIFURCATION STUDY III: A Prospective Randomized Trial of Side Branch Dilatation Strategies in Patients with Coronary Bifurcation Lesions Undergoing Treatment with a Single Stent

FAUST: A Prospective Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access

WHERE:

The Moscone Center
San Francisco, CA

Source:
Judy Romero
Cardiovascular Research Foundation

• Additional
• References
• Citations